Literature DB >> 27016308

APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.

Brandon Leonard1, Gabriel J Starrett1, Matthew J Maurer2, Ann L Oberg2, Mieke Van Bockstal3, Jo Van Dorpe3, Olivier De Wever4, Jozien Helleman5, Anieta M Sieuwerts5, Els M J J Berns5, John W M Martens5, Brett D Anderson1, William L Brown1, Kimberly R Kalli6, Scott H Kaufmann7, Reuben S Harris8.   

Abstract

PURPOSE: APOBEC3 DNA cytosine deaminase family members normally defend against viruses and transposons. However, deregulated APOBEC3 activity causes mutations in cancer. Because of broad expression profiles and varying mixtures of normal and cancer cells in tumors, including immune cell infiltration, it is difficult to determine where different APOBEC3s are expressed. Here, we ask whether correlations exist between APOBEC3 expression and T-cell infiltration in high-grade serous ovarian cancer (HGSOC), and assess whether these correlations have prognostic value. EXPERIMENTAL
DESIGN: Transcripts for APOBEC3G, APOBEC3B, and the T-cell markers, CD3D, CD4, CD8A, GZMB, PRF1, and RNF128 were quantified by RT-qPCR for a cohort of 354 HGSOC patients. Expression values were correlated with each other and clinical parameters. Two additional cohorts were used to extend HGSOC clinical results. Immunoimaging was used to colocalize APOBEC3G and the T-cell marker CD3. TCGA data extended expression analyses to additional cancer types.
RESULTS: A surprising positive correlation was found for expression of APOBEC3G and several T cell genes in HGSOC. Immunohistochemistry and immunofluorescent imaging showed protein colocalization in tumor-infiltrating T lymphocytes. High APOBEC3G expression correlated with improved outcomes in multiple HGSOC cohorts. TCGA data analyses revealed that expression of APOBEC3D and APOBEC3H also correlates with CD3D across multiple cancer types.
CONCLUSIONS: Our results identify APOBEC3G as a new candidate biomarker for tumor-infiltrating T lymphocytes and favorable prognoses for HGSOC. Our data also highlight the complexity of the tumor environment with respect to differential APOBEC family gene expression in both tumor and surrounding normal cell types. Clin Cancer Res; 22(18); 4746-55. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27016308      PMCID: PMC5026552          DOI: 10.1158/1078-0432.CCR-15-2910

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  49 in total

Review 1.  The restriction factors of human immunodeficiency virus.

Authors:  Reuben S Harris; Judd F Hultquist; David T Evans
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

2.  Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms.

Authors:  Beth K Thielen; John P McNevin; M Juliana McElrath; Brook Vander Stoep Hunt; Kevin C Klein; Jaisri R Lingappa
Journal:  J Biol Chem       Date:  2010-07-08       Impact factor: 5.157

3.  A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.

Authors:  Vincent Caval; Rodolphe Suspène; Milana Shapira; Jean-Pierre Vartanian; Simon Wain-Hobson
Journal:  Nat Commun       Date:  2014-10-09       Impact factor: 14.919

4.  Cigarette smoking alters epithelial apoptosis and immune composition in murine GALT.

Authors:  Stephanie Verschuere; Ken R Bracke; Tine Demoor; Maud Plantinga; Phebe Verbrugghe; Liesbeth Ferdinande; Bart N Lambrecht; Guy G G Brusselle; Claude A Cuvelier
Journal:  Lab Invest       Date:  2011-05-02       Impact factor: 5.662

5.  The roles of APOBEC3B in gastric cancer.

Authors:  Jian Zhang; Wei Wei; Hui-Cheng Jin; Rong-Chao Ying; A-Kao Zhu; Fang-Jie Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  APOBEC3B is an enzymatic source of mutation in breast cancer.

Authors:  Michael B Burns; Lela Lackey; Michael A Carpenter; Anurag Rathore; Allison M Land; Brandon Leonard; Eric W Refsland; Delshanee Kotandeniya; Natalia Tretyakova; Jason B Nikas; Douglas Yee; Nuri A Temiz; Duncan E Donohue; Rebecca M McDougle; William L Brown; Emily K Law; Reuben S Harris
Journal:  Nature       Date:  2013-02-06       Impact factor: 49.962

7.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Authors:  Eric W Refsland; Mark D Stenglein; Keisuke Shindo; John S Albin; William L Brown; Reuben S Harris
Journal:  Nucleic Acids Res       Date:  2010-03-22       Impact factor: 16.971

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 9.  Molecular mechanisms of antibody somatic hypermutation.

Authors:  Javier M Di Noia; Michael S Neuberger
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

10.  Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.

Authors:  Valdimara C Vieira; Brandon Leonard; Elizabeth A White; Gabriel J Starrett; Nuri A Temiz; Laurel D Lorenz; Denis Lee; Marcelo A Soares; Paul F Lambert; Peter M Howley; Reuben S Harris
Journal:  mBio       Date:  2014-12-23       Impact factor: 7.867

View more
  23 in total

1.  Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.

Authors:  Laura Evgin; Amanda L Huff; Timothy Kottke; Jill Thompson; Amy M Molan; Christopher B Driscoll; Matthew Schuelke; Kevin G Shim; Phonphimon Wongthida; Elizabeth J Ilett; Karen Kaluza Smith; Reuben S Harris; Matt Coffey; Jose S Pulido; Hardev Pandha; Peter J Selby; Kevin J Harrington; Alan Melcher; Richard G Vile
Journal:  Cancer Immunol Res       Date:  2019-04-02       Impact factor: 11.151

2.  Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.

Authors:  Anna Julia Wiecek; Daniel Hadar Jacobson; Wojciech Lason; Maria Secrier
Journal:  Front Cell Dev Biol       Date:  2021-07-09

3.  The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.

Authors:  Artur A Serebrenik; Prokopios P Argyris; Matthew C Jarvis; William L Brown; Martina Bazzaro; Rachel I Vogel; Britt K Erickson; Sun-Hee Lee; Krista M Goergen; Matthew J Maurer; Ethan P Heinzen; Ann L Oberg; Yajue Huang; Xiaonan Hou; S John Weroha; Scott H Kaufmann; Reuben S Harris
Journal:  Clin Cancer Res       Date:  2020-02-14       Impact factor: 12.531

4.  Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells.

Authors:  Hyunho Kim; Okran Kim; Myung Ah Lee; Ji Youl Lee; Sung-Hoo Hong; U-Syn Ha; Kwangil Yim; In-Ho Kim
Journal:  Curr Oncol       Date:  2021-04-28       Impact factor: 3.677

5.  Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.

Authors:  Subramanian Venkatesan; Mihaela Angelova; Clare Puttick; Haoran Zhai; Deborah R Caswell; Wei-Ting Lu; Michelle Dietzen; Panagiotis Galanos; Konstantinos Evangelou; Roberto Bellelli; Emilia L Lim; Thomas B K Watkins; Andrew Rowan; Vitor H Teixeira; Yue Zhao; Haiquan Chen; Bryan Ngo; Lykourgos-Panagiotis Zalmas; Maise Al Bakir; Sebastijan Hobor; Eva Grönroos; Adam Pennycuick; Ersilia Nigro; Brittany B Campbell; William L Brown; Ayse U Akarca; Teresa Marafioti; Mary Y Wu; Michael Howell; Simon J Boulton; Cosetta Bertoli; Tim R Fenton; Robertus A M de Bruin; Apolinar Maya-Mendoza; Eric Santoni-Rugiu; Robert E Hynds; Vassilis G Gorgoulis; Mariam Jamal-Hanjani; Nicholas McGranahan; Reuben S Harris; Sam M Janes; Jirina Bartkova; Samuel F Bakhoum; Jiri Bartek; Nnennaya Kanu; Charles Swanton
Journal:  Cancer Discov       Date:  2021-05-04       Impact factor: 38.272

Review 6.  Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.

Authors:  Richard Greil; Evelyn Hutterer; Tanja Nicole Hartmann; Lisa Pleyer
Journal:  Cell Commun Signal       Date:  2017-01-19       Impact factor: 5.712

Review 7.  RNA binding to APOBEC deaminases; Not simply a substrate for C to U editing.

Authors:  Harold C Smith
Journal:  RNA Biol       Date:  2016-11-21       Impact factor: 4.652

Review 8.  Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution.

Authors:  S Venkatesan; R Rosenthal; N Kanu; N McGranahan; J Bartek; S A Quezada; J Hare; R S Harris; C Swanton
Journal:  Ann Oncol       Date:  2018-03-01       Impact factor: 32.976

Review 9.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

10.  The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis.

Authors:  Gabriel J Starrett; Elizabeth M Luengas; Jennifer L McCann; Diako Ebrahimi; Nuri A Temiz; Robin P Love; Yuqing Feng; Madison B Adolph; Linda Chelico; Emily K Law; Michael A Carpenter; Reuben S Harris
Journal:  Nat Commun       Date:  2016-09-21       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.